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Abstract
Background: In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan 
(GVAP) that set a target to eliminate measles and rubella in five of the six World Health 
Organization (WHO) regions by 2020. Significant progress has been made toward achieving this 
goal through intensive efforts by countries and Measles & Rubella Initiative (M&RI) partners. 
Accelerating progress will require evidence-based approaches to improve implementation of the 
core strategies in the Global Measles and Rubella Strategic Plan. The M&RI Research and 
Innovation Working Group (R&IWG) conducted a web-based survey as part of a process to 
identify measles and rubella research priorities. Survey findings were used to inform discussions 
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during a meeting of experts convened by the M&RI at the Pan American Health Organization in 
November 2016.
Methods: The cross-sectional web-based survey of scientific and programmatic experts included 
questions in four main topic areas: (1) epidemiology and economics (epidemiology); (2) new tools 
for surveillance, vaccine delivery, and laboratory testing (new tools); (3) immunization strategies 
and outbreak response (strategies); and (4) vaccine demand and communications (demand). 
Analyses were stratified by the six WHO regions and by global, regional, or national/sub-national 
level of respondents.
Results: The six highest priority research questions selected by survey respondents from the four 
topic areas were the following: (1) What are the causes of outbreaks in settings with high reported 
vaccination coverage? (epidemiology); (2) Can affordable diagnostic tests be developed to confirm 
measles and rubella cases rapidly and accurately at the point of care? (new tools); (3) What are 
effective strategies for increasing coverage of the routine first dose of measles vaccine 
administered at 9 or 12 months? (strategies); (4) What are effective strategies for increasing 
coverage of the second dose given after the first year of life? (strategies); (5) How can 
communities best be engaged in planning, implementing and monitoring health services including 
vaccinations? (demand); (6) What capacity building is needed for health workers to be able to 
identify and work more effectively with community leaders? (demand). Research priorities varied 
by region and by global/regional/ national levels for all topic areas.
Conclusions: Research and innovation will be critical to make further progress toward 
achieving the GVAP measles and rubella elimination goals. The results of this survey can be used 
to inform decision-making for investments in research activities at the global, regional, and 
national levels.
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1 Introduction
The Global Vaccine Action Plan (GVAP), endorsed by the World Health Assembly (WHA) 
in 2012, established a global goal to achieve elimination of measles, rubella, and congenital 
rubella syndrome (CRS) by 2020 in five of the six World Health Organization (WHO) 
regions [1,2]. Additionally, as of September 2013, all WHO regions have set regional goals 
to achieve measles elimination by 2020, and three have established a goal for rubella 
elimination [3]. The Measles & Rubella Initiative (M&RI), led by the American Red Cross, 
the United Nations Foundation, the U.S. Centers for Disease Control and Prevention (CDC), 
the United Nations Children’s Fund (UNICEF), and WHO, established the Global Measles 
and Rubella Strategic Plan, 2012–2020 [2]. The plan contains targets aligned with the GVAP 
and outlines five implementation strategies for achieving measles and rubella elimination 
goals: (1) achieve and maintain high levels of population immunity by providing high 
vaccination coverage with two doses of measles- and rubella-containing vaccines; (2) 
monitor disease using effective surveillance and evaluate programmatic efforts to ensure 
progress; (3) develop and maintain outbreak preparedness, respond rapidly to outbreaks, and 
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manage cases; (4) communicate and engage to build public confidence and demand for 
immunization; and (5) perform the research and development needed to support cost-
effective operations and improve vaccination and diagnostic tools [2].
Significant progress has been made toward achieving measles and rubella elimination 
through intensive efforts by various countries and M&RI partners. Global reported measles 
cases declined from 853,479 in 2000 to 173,330 in 2017, a decrease of 80% [4]. During this 
same period, the annual number of estimated measles deaths decreased by 80%, from 
545,174 to 109,638 [4]. Estimated coverage with the routine first dose of measles-containing 
vaccine (MCV1) increased from 72% in 2000 to 85% in 2010 globally, and plateaued at 84–
85% during 2010–2017; the number of countries with ≥90% MCV1 coverage increased 
from 84 in 2000 to 118 in 2017 [5]. The number of countries providing the recommended 
routine second dose of measles-containing vaccine (MCV2) increased from 97 in 2000 to 
160 in 2016 [6]; estimated MCV2 coverage increased from 15% in 2000 to 67% in 2017 
globally [5]. During 2000–2017, estimated rubella-containing vaccine coverage increased 
globally from 22% to 52%, and the number of rubella cases reported globally declined 97% 
from 670,894 in 2010 to 22,361 in 2016 [5,7].
The Region of the Americas verified elimination of measles in May 2016 and rubella in 
September 2015 [8], but a recent measles outbreak in Venezuela led to reestablished 
endemic measles because of the sustained transmission of measles virus for >12 months [4]. 
In 2018, the outbreak continued with more than 6,300 confirmed measles cases and 70 
measles deaths. The other five WHO regions have made progress but will require further 
efforts to achieve measles and rubella elimination goals. In 2016, a midterm review of the 
Global Measles and Rubella Strategic Plan (2012–2020) concluded that the plan’s core 
strategies were sound and recommended that countries continue to work toward elimination 
goals with a focus on strengthening their immunization systems and improving 
implementation of the core strategies. The review concluded that full implementation of the 
strategies had been impeded by inadequate country ownership and global political will and 
emphasized the need to invest in innovation [9,10].
Despite the substantial progress in increasing coverage of measles and rubella vaccines and 
in reducing the burden of measles and rubella, there are a number of unanswered questions 
on how to implement the strategies most effectively and efficiently to accelerate measles and 
rubella elimination. The M&RI Research and Innovation Work Group (R&IWG) is a group 
of experts appointed by the M&RI for their recognized expertise in measles and rubella that 
works with government agencies, implementing partners, and academic institutions to 
monitor and coordinate research, and prioritize research areas for focus [11]. The R&IWG 
conducted a survey of scientific and programmatic experts to identify measles and rubella 
research questions considered high priority for accelerating elimination efforts. Experts were 
invited to complete the survey using a list of contacts compiled by the R&IWG from 
established measles and rubella committees, previous measles and rubella meetings, and 
input from measles and rubella implementing partner focal points. The survey results were 
presented at a meeting of 40 experts with measles and rubella elimination effort experience 
from all six WHO regions, held at the Pan American Health Organization (PAHO) in 
Washington, D.C. in November 2016 where deliberations and recommendations on research 
Kriss et al. Page 3
Vaccine. Author manuscript; available in PMC 2020 September 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
priorities were made [12]. The survey results were used as critical inputs for the M&RI 
comprehensive research prioritization process, but were just one of several data sources that 
informed the M&RI research agenda-setting meeting [13].
2 Methods
2.1. Study design and recruitment
A cross-sectional web-based survey was conducted by asking experts on measles and/or 
rubella about research priorities for achieving disease elimination goals. Before conducting 
the survey, CDC and the M&RI held an hour-long webinar on October 17, 2016, discussing 
measles and rubella elimination goals and research priorities. The webinar was promoted 
through global measles and rubella networks; it was recorded and posted on the M&RI 
website [14]. After the initial webinar, invitations to complete the survey were emailed to 
774 experts in the field of measles and rubella, based on a list of experts compiled by the 
R&IWG with input from M&RI partners. The email recipients were asked to forward the 
survey invitation to other appropriate persons working on measles and rubella, in order to 
increase participation and inclusivity and ensure that we received responses from a variety of 
individuals working in measles and rubella at the country and local levels. The survey was 
open for completion during October 17–November 4, 2016. Reminder emails were sent to 
non-responders and to individuals who began the survey but only partially completed it.
2.2. Survey questions
A list of research questions was generated by the R&IWG based on findings from previous 
research prioritization activities published by Goodson et al. [15] and presented by Moss et 
al. in a report to the Strategic Advisory Group of Experts (SAGE) on Immunization Working 
Group on Measles and Rubella [16]. The research questions were categorized into four 
research topic areas: (1) epidemiology and economics; (2) new tools for surveillance, 
vaccine delivery, and laboratory testing; (3) immunization strategies and outbreak response; 
and (4) vaccine demand and communications. The survey presented the list of research 
questions and asked respondents to rate each question’s significance (highly significant, 
moderately significant, low significance, not significant) and urgency (as soon as possible, 
by 2020, not essential by 2020) in order to achieve global and regional measles and rubella 
elimination goals (Supplemental Table). From the list of research questions, respondents 
were also asked to select the three research questions they considered of highest priority to 
achieve measles and rubella global and regional elimination goals. Additionally, respondents 
were asked to add key research questions they thought were missing from the list in open 
fields on the survey and to rank those questions with regard to significance and urgency.
2.3. Statistical analysis
For each research question, we calculated the proportion of respondents who selected the 
question as one of their three highest priorities to achieve the measles and rubella global and 
regional elimination goals, by dividing the number of people who selected the research 
question as a high priority by the number of respondents who answered that question. 
Analyses were stratified in two ways: (1) the primary WHO region that each respondent 
Kriss et al. Page 4
Vaccine. Author manuscript; available in PMC 2020 September 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
reported they worked in, and (2) by global, regional, or national/sub-national level of the 
respondents’ work.
3 Results
3.1. Demographics
A total of 207 individuals responded to the web-based survey during October 17–November 
4, 2016, including 145 (70%) who answered all questions in the survey, and 18 (9%) who 
partially completed the survey and whose responses were included for the questions they 
answered. The analysis excluded 44 (21%) individuals who provided demographic data only 
but did not answer any of the questions on research priorities. The survey respondents’ 
immunization experience was from all six WHO regions (Table 1). Respondents were 
categorized by primarily working at the global (n = 39), regional (n = 30), or national/sub-
national (n = 73) level (the remaining 21 respondents were not categorized and were not 
included in analyses stratified by level). Respondents worked for Ministry of Health/
Government (27%), WHO (25%), CDC (14%), academic setting/university (8%), UNICEF 
(7%), John Snow, Inc. (4%), American Red Cross (2%), or as an independent immunization 
consultant (3%). Almost half (48%) had worked on measles and/or rubella for ≥ 10 years, 
28% for 5–9 years, 19% for 1–5 years, and 5% for <1 year. The primary area of 
respondents’ expertise was reported as both measles and rubella (44%), routine 
immunization service delivery (25%), measles only (11%), rubella only (2%), or other 
(18%). The most common primary scopes of work (respondents could select more than one 
area) were epidemiology (51%), routine immunization service delivery (50%), field 
surveillance (44%), outbreak response (43%), campaigns (41%), vaccine delivery (28%), 
and research (28%). Smaller numbers said that they worked in communications (15%), 
health behavior (5%), economics (5%), and mathematical modeling (2%).
3.2. Epidemiology and economics (Fig. 1)
The epidemiology and economics research question selected by the largest percentage (46%) 
of respondents as a high priority was: “What are the causes of outbreaks in settings with 
high reported vaccination coverage?” This question was most frequently listed by 
respondents in the African Region (AFR), the Region of the Americas (AMR), the European 
Region (EUR), and the Western Pacific Region (WPR). Respondents working at the national 
or sub-national level, in particular, selected this question as high priority. The second most 
selected (34%) research question in this category was: “What are the epidemiologic 
characteristics of measles (e.g., incidence, age distribution, case fatality ratios) in various 
settings in priority countries?” This question was identified particularly in the Eastern 
Mediterranean Region (EMR), where 63% of respondents selected it as a high priority. It 
was a high priority for respondents across global, regional, and national levels. The third 
most frequently chosen (27%) research question in this category was the following: “What 
are the best methods for measuring progress toward measles and rubella elimination?” This 
question was a high priority for 20–34% of respondents across all regions and across global, 
regional, and national levels.
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In the South-East Asia Region (SEAR), the most frequently chosen research question (62%) 
was “What is the optimal age of 1st and 2nd doses of routine measles vaccination in 
different epidemiological settings? What are potential implications of receiving MCV1 at an 
early age (e.g., prior to 9 months)?” In WPR and AMR, the second most frequently chosen 
research question (55% and 40% of respondents, respectively) was “What is the prevalence 
of measles and rubella susceptibility among adolescents and adults in settings with persistent 
suboptimal coverage, and what is their role in sustaining transmission?” In EMR, the 
following questions were selected frequently (38% each): “What is the need to vaccinate 
older children, adolescents, and adults in SIAs,” and “What is the cost of the level of 
surveillance needed to achieve measles and rubella elimination?” The research question, 
“Can adults sustain measles virus transmission in the presence of high child immunity 
levels, thereby making adult vaccination necessary to reach and maintain elimination,” was 
the most frequently selected question for respondents working at the global level (32%) and 
the second most chosen for respondents working in WPR (36%). Three economics research 
questions were presented in the survey as potential priorities. The economic research 
question selected most frequently (17%) was “What is the cost of the level of surveillance 
needed to achieve measles and rubella elimination?” Survey respondents also provided new 
epidemiology and economics research questions that they thought were missing from those 
listed in the survey [17].
3.3. Surveillance, vaccine delivery, and laboratory testing (Fig. 2)
The surveillance, vaccine delivery, and laboratory testing research question selected by the 
largest percentage (68%) of respondents as a high priority was: “Can affordable diagnostic 
tests be developed to rapidly and accurately confirm measles and rubella cases at the point of 
care?” This question was selected most frequently by respondents across global, regional, 
and national levels, and in all regions except for EMR and WPR (ranging from 67% in AMR 
to 77% in SEAR, and up to 84% among those working at the regional level). The second 
most frequently selected (60%) research question in this category was: “Can vaccine safety, 
effectiveness, and/or coverage be improved by developing more thermo-stable vaccines, 
advanced vaccine vial temperature monitors, self-reconstituting vials, or by alternative 
delivery methods (e.g., needle-free injection devices, aerosol, dry powder inhalation, 
microneedles)?” This question was particularly important in WPR, where it was selected by 
the largest percentage of respondents (80%). It was chosen as a high priority question by a 
majority of respondents across global, regional, and national levels. The third highest (42%) 
priority research question in this category was “What is the effectiveness of 2 or more doses 
of measles-containing vaccine for achieving elimination in high birth rate, densely populated 
settings in developing countries?” This question, that is related to better understanding basic 
reproduction number (R0) values and herd immunity thresholds in various settings, was 
selected as high priority by large proportions of survey respondents in SEAR (69%) and 
EMR (57%), in particular. It was also chosen as high priority among a majority of experts 
working at the national or sub-national level (52%).
Two additional research questions were selected by more than one-quarter of respondents as 
high priority. The question “What is the most appropriate method for determining level of 
population immunity in developing countries?” was selected by 26% of all respondents, by 
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60% of WPR respondents, and by 36% of regional level respondents. The question “What 
are valid performance indicators for measles and rubella case-based surveillance in different 
settings?” was selected by 28% of all respondents and by 39% of global level respondents. 
Survey respondents provided new key surveillance, vaccine delivery, and laboratory testing 
research questions that they thought were missing from those listed in the survey [17].
3.4. Immunization strategies and outbreak response (Fig. 3)
Two research questions pertaining to immunization strategies and outbreak response were 
selected by a majority (53% each) of respondents as high priority. The first question was 
“What are effective strategies for increasing coverage of the routine first dose of measles 
vaccine administered at 9 or 12 months?” The second question was “What are effective 
strategies for increasing coverage of the second dose given after the first year of life?” First 
dose coverage was selected particularly in AMR (67%), and second dose coverage was 
selected by more than two-thirds of respondents (70%) in WPR.
The second most frequently selected (46%) research question in this category was: “What 
are effective strategies for identifying and vaccinating geographic or culturally hard-to-reach 
populations (e.g., nomadic populations, migrants, refugees, and internally displaced persons) 
in various settings?” This question was chosen as high priority by ≥ 38% of respondents 
across regions and by ≥ 43% of respondents across global, regional and national levels. It 
was the most frequently selected question in EUR (62%). The third most commonly selected 
(30%) research question in this category was “What are accurate, efficient, and novel 
methods for monitoring/verifying first- and second-dose measles vaccination coverage 
through routine immunization services and SIAs (e.g., serosurveys, coverage surveys, etc.)?” 
This question was selected as highest priority by 46% of survey respondents in SEAR. It 
was infrequently chosen as a high priority question by experts working at the global level 
(6%), but it was more frequently selected among experts working at regional or national/
sub-national levels (43% and 38%, respectively).
Respondents from EMR and SEAR tended to select different research questions as high 
priority compared to respondents in the other regions. In SEAR, nearly half (46%) of 
respondents listed two research questions as high priority: “What are the most cost-effective 
strategies for outbreak response immunization activities, including the timing of outbreak 
response immunization and selection of target populations?” EMR respondents most 
frequently (67%) selected the research question “What are effective strategies (e.g., house-
to-house social mobilization) to maximize SIA coverage in different epidemiological 
settings?” Respondents working at the regional level were particularly interested in this 
research question as well; 52% selected this question as high priority. Survey respondents 
provided new key research questions in the immunization strategies and outbreak response 
category that they thought were missing from those listed in the survey [17].
3.5. Vaccine demand and communications (Fig. 4)
The vaccine demand and communications research question selected by the largest 
percentage (53%) of respondents was: “How can communities best be engaged in planning, 
implementing and monitoring health services including vaccinations? What capacity 
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building is needed for health workers to be able to identify and work more effectively with 
community leaders?” This question was selected by a majority of survey respondents in 
AFR (70%), EMR (50%), SEAR (62%), and WPR (50%). It was also chosen frequently by 
experts working at the regional and national levels (58% each), but less so by global level 
experts (39%).
The second most commonly chosen (41%) research question in this category was “What are 
community attitudes and perceptions related to health services, immunizations, measles and 
rubella vaccination, and SIAs?” This question was selected by a majority of respondents in 
SEAR (62%) and by experts working at the national/ sub-national level (52%). The third 
most frequently selected research question in this category was “What misconceptions and 
attitudinal barriers exist among public and private sector health care providers regarding 
measles- and rubella-containing vaccines?” This question was selected by 37% of all survey 
respondents and by 50% and 62% of respondents from EMR and EUR, respectively.
There was more variation among respondents in prioritizing research questions in the 
vaccine demand and communications topic area than in the other research topic areas. 
Although the“community engagement”201D research question was selected as high priority 
by most respondents overall and was the most frequently cited research question by 
respondents in four regions (AFR 70%, EMR 50%, SEAR 62%, WPR 50%), respondents 
from three of those regions (EMR, SEAR, WPR) rated at least one other question a high 
priority with the same frequency. Respondents in AMR selected a different research question 
as highest priority (46%): “What are the most effective evidence-based strategies for measles 
and rubella vaccine acceptance?” Among global level respondents, the most frequently 
chosen (50%) question was “What are the best strategies to address information gaps or 
confidence gaps in measles and rubella vaccines in different settings?” Survey respondents 
provided new key vaccine demand and communications research questions that they thought 
were missing from those listed in the survey [17].
4 Discussion
Research and innovation will be critical to accelerate progress toward achieving the GVAP 
goal to eliminate measles, rubella, and CRS in five of the six WHO regions by 2020 [1,3]. It 
will be vital to continue to identify and prioritize research questions with the greatest 
potential impact on achieving elimination goals, and these will likely vary by region [15]. 
Previous research prioritization efforts for measles and rubella/CRS have been done by 
consensus among subject matter experts (SMEs) participating in collaborative meetings or 
by expert input through surveys [15,16]. The recent M&RI measles and rubella research 
prioritization process combined both approaches. The web-based survey described in this 
report provided results that were used during the November 2016 meeting of experts to 
inform discussions about research priorities in four main topic areas: (1) epidemiology and 
economics; (2) new tools for surveillance, vaccine delivery, and laboratory testing; (3) 
immunization strategies and outbreak response; and (4) vaccine demand and 
communications. Data from the survey were reviewed by SMEs in topic-based workgroups 
during the meeting, considered along with results from previous research prioritization 
activities, and used to identify research priorities for accelerating measles and rubella 
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elimination. The findings from the collaborative meeting of experts are presented in an 
accompanying paper [13].
Across WHO regions and at the global, regional, and national/ sub-national levels, there was 
considerable agreement by experts on measles and rubella research priorities. Overall, the 
research questions that were selected as high priority by the most survey respondents 
pertained to the development of new technologies to improve vaccination and diagnosis of 
disease. The priority research question listed by the most (68%) respondents addressed 
whether affordable diagnostic tests can be developed to confirm measles and rubella cases 
rapidly and accurately at the point of care. Another high priority research question, chosen 
by 60% of all respondents, addressed whether vaccine safety, effectiveness, and/or coverage 
can be improved by developing more thermo-stable vaccines, advanced vaccine vial 
temperature monitors, self-reconstituting vials, or by alternative delivery methods (e.g., 
needle-free injection devices, aerosol, dry powder inhalation, microneedles).
In three of the research topic areas, there was agreement on the highest priority research 
questions by respondents from at least four of the six regions. However, there appeared to be 
some differences in priorities worth noting. Experts working at the global level more 
frequently cited questions related to strategies to address information gaps or confidence 
gaps for measles and rubella vaccines (50%), and the need for better understanding of the 
role of adults in sustaining virus transmission and the potential need for adult vaccination 
(32%). Experts working at the national or sub-national level appeared to place more priority 
on questions regarding the causes of outbreaks in high-coverage settings (62%); the 
effectiveness of vaccination in densely populated developing country settings (52%); and 
community attitudes and perceptions of health services, immunization, measles and rubella 
vaccination, and SIAs (52%). In the Americas, the only region that achieved elimination of 
both measles and rubella, but where a recent measles outbreak in Venezuela with sustained 
transmission of measles virus for >12 months led to reestablished endemic measles [4], 
experts were more concerned with questions related to evidence-based strategies for vaccine 
acceptance (46%) and susceptibility among adolescents and adults and their role in 
sustaining transmission (40%). The vaccine demand and communications topic area had 
more regional heterogeneity in priority questions than the other topic areas. Almost half of 
respondents reported working in measles/rubella programs for ≥10 years, so it is possible 
that compared with respondents with less time working in measles/rubella, they may have 
less independent perspective and their responses may incremental progress rather than more 
innovative research that could lead to more significant change.
The results of this survey should be viewed in light of some limitations. First, respondents to 
the survey were a convenience sample; 774 measles and rubella experts were identified by 
the R&IWG with input from M&RI partners and were directly invited to complete the 
survey, and invitees were asked to forward the survey invitation to other experts working on 
measles and rubella. We selected this sampling strategy in order to increase inclusivity and 
ensure that we received input from a variety of experts working in measles and rubella at the 
country and local levels who might not have been identified for the initial invitation list. This 
strategy helped to increase participation in the survey but the exact number of individuals 
who received a survey invitation was unknown; therefore, the survey response rate could not 
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be calculated. Further, even with this sampling strategy it is possible that some measles and 
rubella experts did not receive a survey invitation, with a higher likelihood among those 
working at the local level. Comparing the invite list to the list of respondents, 30 individuals 
who completed the survey were not on the original invite list, so likely received a forwarded 
survey invite. The survey was conducted using the internet and in English, so individuals 
with poor internet connection or in non-English-speaking settings were likely 
underrepresented among survey respondents. We received some non-English responses that 
were translated and included in the results; however, it is possible that other non-English 
speaking invitees did not participate in the survey due to a language barrier. Second, the list 
of research questions presented in the survey was developed by a group of M&RI experts. 
Although this list was intended to be comprehensive, it was likely biased by the experts’ 
own knowledge and subjective priorities. Open-ended response questions were purposefully 
included in the survey to allow respondents to provide additional key research questions that 
were not already in the survey. Through open-ended responses, survey participants identified 
additional high priority research questions that were missing from those listed specifically in 
the survey. Although this was important information, not all survey respondents ranked these 
additional research questions, and quantitative analysis of these open-ended responses was 
not possible. However, this information was shared at the meeting of experts in November 
2016 and considered during the comprehensive prioritization process. Third, the design and 
structural organization of the survey could have had an impact on the way respondents 
ranked priorities. For example, epidemiology topics and economics topics were categorized 
together, and so research questions from both topics were compared against each other in 
rankings. Thus, we found that in the epidemiology and economics topic area, research 
questions with the highest priorities were related to epidemiology, and three research 
questions related to economics were ranked as lower priority. Similarly, some questions 
were composites which combined multiple innovations in the same question. This style of 
question may have increased the likelihood of ranking these questions more highly 
compared with a question on a single topic area.
Global research priorities will continue to evolve with further progress toward achieving the 
GVAP goals and as countries and regions move closer toward measles and rubella 
elimination. This is evident in the Americas, which had achieved elimination, and whose 
respondents have different priorities than other regions. Periodic assessments of research 
priorities through future research prioritization processes will be critical to focus research 
projects and guide investments by stakeholders. Implementation of research to address the 
identified priorities will be instrumental in accelerating progress toward elimination and 
eventual eradication of measles and rubella. The R&IWG will estimate the scale of funds 
required, and identify potential sources of research funding opportunities and 
implementation partners to ensure that research and innovation activities provide the 
evidence that will be critical for setting policies and refining elimination strategies for 
success.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Epidemiology and economics research priorities, Measles & Rubella Initiative web-based 
survey, 2016 (n = 157). Note: Other epidemiology and economics research questions that 
were selected by fewer respondents as a priority: What are the best methods to estimate the 
threshold population size and susceptible density required to sustain measles and/or rubella 
virus transmission in various settings? (11%); What is the economic burden of measles 
outbreaks in low- and middle-income countries? (11%); What are the best methods for 
measuring disease burden of measles and rubella? (8%); What is the epidemiology of 
rubella/CRS in developing countries with different birth rates? (8%); What is the prevalence 
of measles virus susceptibility among human immunodeficiency virus (HIV)-infected adults 
in high HIV-prevalence settings and does this depend on coverage of highly active 
antiretroviral therapy (HAART)? (4%); What is the economic burden of CRS at global, 
regional and national levels? Does the economic burden differ for low- and middle-income 
countries? (3%).
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Fig. 2. 
Surveillance, vaccine delivery, and laboratory testing research priorities, Measles & Rubella 
Initiative web-based survey, 2016 (n = 144). Note: Other surveillance, vaccine delivery, and 
laboratory testing research questions that were selected by fewer respondents as a high 
priority: What are the technical requirements and epidemiologic utility of developing 
serologic assays to differentiate immunity acquired from exposure to wild-type viruses and 
immunity acquired from exposure to vaccine strains? (9%); Can tests be developed to 
accurately measure neutralizing antibodies to measles and rubella viruses, and provide 
results faster than the plaque reduction neutralization assay (PRNT)? (8%).
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Fig. 3. 
Immunization strategies and outbreak response research priorities, Measles & Rubella 
Initiative web-based survey, 2016 (n = 142)
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Fig. 4. 
Vaccine demand and communications research priorities, Measles & Rubella Initiative web-
based survey, 2016 (n = 144).
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